Because PIK75 is not clinically available, we combined BGT226 (selective inhibitor of PI3K p110α subunit and mTOR) with STA9090 and found potent synergistic in vitro and in vivo antiproliferative effect in ACC cells and patient-derived organoids (PDOs). Here, MTOR is linked to adrenal cortex carcinoma.